TP53 and ovarian cancer: In a clinical trial involving 121 TP53-mutant platinum-sensitive ovarian cancer patients, the addition of adavosertib (MK-1775) to carboplatin and paclitaxel improved progression-free survival by 1.9 months compared to placebo plus the combination chemotherapy.